BlueCross BlueShield
Federal Employee Program

INLYTA
PRIOR APPROVAL REQUEST

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Patient Information (required)			**Provider Information (required)**		
Date:			Provider Name:		
Patient Name:			Specialty:	NPI:	
Date of Birth:	Sex: ❑Male ❑Female		Office Phone:	Office Fax:	
Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:
Patient ID: **R**			Physician Signature:		
PHYSICIAN COMPLETES					

Inlyta (axitinib)

****Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit**

NOTE: Form must be completed in its **entirety** for processing

Is this request for brand or generic? ❑Brand ❑Generic

1. What is the patient's diagnosis?
   - ❑ Advanced renal cell carcinoma
   - ❑ Other diagnosis ***(please specify):*** _____

2. Has the patient been on Inlyta continuously for the last **6 months**, excluding samples? ***Please select answer below:***

   ❑**NO** – this is **INITIATION** of therapy, please answer the following questions:

   a. Has the patient failed a prior ***first-line systemic therapy? ❑Yes ❑No

   First-Line Systemic Therapy: Sutent (sunitinib), Avastin (bevacizumab), Torisel (temsirolimus), Nexavar (sorafenib), Afinitor (everolimus), Votrient (pazopanib), and Cytokines (interferon-alpha, interleukin-2)

   b. Will Inlyta be used in combination with Keytruda (pembrolizumab) as first-line treatment? ❑Yes ❑No

   c. Will Inlyta be used in combination with Bavencio (avelumab) as first-line treatment? ❑Yes ❑No

   d. Will the patient's ALT, AST, and bilirubin be obtained prior to initiation of therapy and be monitored during therapy? ❑Yes ❑No

   ❑**YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following questions:

   a. Does the patient have gastrointestinal perforation or fistula? ❑Yes ❑No

   b. Does the patient have signs and symptoms of reversible posterior leukoencephalopathy syndrome (RPLS)? ❑Yes ❑No

   c. Does the patient have severe hepatic impairment? ❑Yes ❑No

BlueCross BlueShield
Federal Employee Program

INLYTA
PRIOR APPROVAL REQUEST

Send completed form to:
Service Benefit Plan
Prior Approval
P.O. Box 52080 MC 139
Phoenix, AZ 85072-2080
Attn. Clinical Services
Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 **minutes** **FASTEST AND EASIEST**	Now you can get responses to drug Prior Authorization requests **securely** online. **Online** submissions may receive **instant** responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to **Caremark.com/ePA.**
Phone (4-5 **minutes** for response)	The FEP Clinical Call Center can be reached at **(877)-727-3784** between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 **days** for response)	Fax the attached form to **(877)-378-4727**. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. ***Please only fax the completed form once as duplicate submissions may delay processing times.***